The Lin group’s findings demonstrated that HuR suppression enhanced epirubicin sensitivity in colon cancer cell lines in vitro, suggesting its potential as a combinatorial treatment to reverse chemotherapeutic drug resistance. The gene discussed is ELAVL1; the disease is malignant colon neoplasm.